In particular, a biophysical mathematical model to predict tumor response for two HER2 + breast cancer patients was defined by Jarret et al. using quantitative data from MRI and 64Cu-DOTA-trastuzumab PET to estimate tumor density, perfusion, and distribution of HER2-targeted antibodies for each individual patient. This evidence concerns the gene ERBB2 and breast cancer.